JP2002518051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518051A5 JP2002518051A5 JP2000556036A JP2000556036A JP2002518051A5 JP 2002518051 A5 JP2002518051 A5 JP 2002518051A5 JP 2000556036 A JP2000556036 A JP 2000556036A JP 2000556036 A JP2000556036 A JP 2000556036A JP 2002518051 A5 JP2002518051 A5 JP 2002518051A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- motif
- fragment
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002773 nucleotide Substances 0.000 description 21
- 239000012634 fragment Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 230000001177 retroviral effect Effects 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 101000820777 Homo sapiens Syncytin-1 Proteins 0.000 description 8
- 102100021696 Syncytin-1 Human genes 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 230000003831 deregulation Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- -1 amino Chemical group 0.000 description 4
- IRSFLDGTOHBADP-UHFFFAOYSA-N embelin Chemical compound CCCCCCCCCCCC1=C(O)C(=O)C=C(O)C1=O IRSFLDGTOHBADP-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000713887 Human endogenous retrovirus Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- RESSROXEVCGJLA-DFNTYYFDSA-N 99273-04-8 Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 RESSROXEVCGJLA-DFNTYYFDSA-N 0.000 description 1
- 108010034572 CKS 17 Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000711517 Torovirus Species 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000018412 transposition, RNA-mediated Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9807920A FR2780069B1 (fr) | 1998-06-23 | 1998-06-23 | Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications |
| FR98/07920 | 1998-06-23 | ||
| PCT/FR1999/001513 WO1999067395A1 (fr) | 1998-06-23 | 1999-06-23 | Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains, et leurs applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002518051A JP2002518051A (ja) | 2002-06-25 |
| JP2002518051A5 true JP2002518051A5 (https=) | 2006-07-20 |
Family
ID=9527737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556036A Pending JP2002518051A (ja) | 1998-06-23 | 1999-06-23 | ヒト内因性レトロウイルスモチーフを有する核酸及び推定されるタンパク質配列のファミリーのならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6919438B1 (https=) |
| EP (2) | EP1090122B1 (https=) |
| JP (1) | JP2002518051A (https=) |
| AU (1) | AU4375199A (https=) |
| CA (1) | CA2331923C (https=) |
| DE (1) | DE69939114D1 (https=) |
| FR (1) | FR2780069B1 (https=) |
| WO (1) | WO1999067395A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2221600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP2003512844A (ja) * | 1999-10-28 | 2003-04-08 | ユニヴェルシテ・ドゥ・ジュネーブ | 多発性硬化症関連スーパー抗原 |
| FR2805279B1 (fr) * | 2000-02-23 | 2004-09-24 | Jean Jacques Guilhou | Sequences retrovirales associees a des affections cutanees |
| US20070249808A1 (en) * | 2000-10-30 | 2007-10-25 | Bernard Conrad | Multiple Sclerosis-related superantigen |
| EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| AT411262B (de) | 2001-09-27 | 2003-11-25 | Wolff Klaus Dr | Humanes endogenes retrovirus |
| FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
| JP5060284B2 (ja) * | 2004-03-30 | 2012-10-31 | アンスティテュ・グスターブ・ルシ | ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列 |
| US8680065B2 (en) * | 2008-09-11 | 2014-03-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use |
| DK3676285T3 (da) | 2017-09-01 | 2026-01-19 | Inprother Aps | Vaccine til anvendelse i profylakse og/eller behandling af en sygdom |
| AU2019343045A1 (en) | 2018-09-18 | 2021-05-13 | Vnv Newco Inc. | ARC-based capsids and uses thereof |
| WO2020252455A1 (en) | 2019-06-13 | 2020-12-17 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CN110470837B (zh) * | 2019-08-30 | 2022-09-16 | 苏州西山生物技术有限公司 | 利用猴srv病毒gp20蛋白检测猴srv病毒的方法及其试剂盒 |
| US11129892B1 (en) | 2020-05-18 | 2021-09-28 | Vnv Newco Inc. | Vaccine compositions comprising endogenous Gag polypeptides |
| CA3189601A1 (en) | 2020-07-24 | 2022-01-27 | The General Hospital Corporation | Enhanced virus-like particles and methods of use thereof for delivery to cells |
| WO2023086882A1 (en) * | 2021-11-11 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ279855A (en) * | 1994-02-04 | 1998-05-27 | Bio Merieux | Msrv1 and msrv2 pathogenic and/or infectious agents associated with ms, nucleic acids encoding them and diagnostic and therapeutic applications |
| FR2737500B1 (fr) * | 1995-08-03 | 1997-08-29 | Bio Merieux | Materiel viral et fragments nucleotidiques associes a la sclerose en plaques, a des fins de diagnostic, prophylactiques et therapeutiques |
| US5708157A (en) * | 1996-07-26 | 1998-01-13 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6312921B1 (en) * | 1996-07-26 | 2001-11-06 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| WO1998023755A1 (en) * | 1996-11-26 | 1998-06-04 | Bio Merieux | Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes |
| FR2765588A1 (fr) * | 1997-07-07 | 1999-01-08 | Bio Merieux | Materiel nucleique retroviral et fragments nucleotidiques notamment associes a la sclerose en plaques et/ou la polyarthrite rhumatoide, a des fins de diagnostic, prophylactiques et therapeutiques |
| AU8447098A (en) * | 1997-07-07 | 1999-02-08 | Bio Merieux | Endogenetic retroviral sequences, associated with autoimmune diseases or with pregnancy disorders |
-
1998
- 1998-06-23 FR FR9807920A patent/FR2780069B1/fr not_active Expired - Lifetime
-
1999
- 1999-06-23 EP EP99926538A patent/EP1090122B1/fr not_active Expired - Lifetime
- 1999-06-23 WO PCT/FR1999/001513 patent/WO1999067395A1/fr not_active Ceased
- 1999-06-23 EP EP08010138A patent/EP1997895A1/fr not_active Withdrawn
- 1999-06-23 DE DE69939114T patent/DE69939114D1/de not_active Expired - Lifetime
- 1999-06-23 US US09/719,554 patent/US6919438B1/en not_active Expired - Lifetime
- 1999-06-23 CA CA2331923A patent/CA2331923C/fr not_active Expired - Lifetime
- 1999-06-23 AU AU43751/99A patent/AU4375199A/en not_active Abandoned
- 1999-06-23 JP JP2000556036A patent/JP2002518051A/ja active Pending
-
2005
- 2005-01-05 US US11/028,539 patent/US7534439B2/en not_active Expired - Fee Related
-
2008
- 2008-12-17 US US12/336,813 patent/US20090263783A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002518051A5 (https=) | ||
| Rao et al. | Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome | |
| JP4723550B2 (ja) | 生存運動ニューロン（ｓｍｎ）遺伝子；脊髄筋萎縮 | |
| Pulkkinen et al. | Identification of ABCC6 pseudogenes on human chromosome 16p: implications for mutation detection in pseudoxanthoma elasticum | |
| Albertella et al. | Characterization of a novel gene in the human major histocompatibility complex that encodes a potential new member of the I kappa B family of proteins | |
| Grimm et al. | Isolation and embryonic expression of the novel mouse gene Hic1, the homologue of HIC1, a candidate gene for the Miller-Dieker syndrome | |
| JP2009515524A5 (https=) | ||
| AU2003290715A1 (en) | Method for identifying risk of melanoma and treatments thereof | |
| EP0769053A2 (en) | Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma | |
| CN104450727A (zh) | X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用 | |
| Schmitt et al. | Genomic structure, chromosomal localization, and expression pattern of the human LIM-homeobox3 (LHX 3) gene | |
| CN113355332B (zh) | Heg1基因突变体及其应用 | |
| CN110551728A (zh) | Foxc1基因突变体及其应用 | |
| CN105821062B (zh) | Amsh基因突变体及其应用 | |
| US20020142003A1 (en) | Tumor-associated antigen (B345) | |
| WO1998007748A2 (en) | Plag gene family and tumorigenesis | |
| CA2461199A1 (en) | Atlastin | |
| JP2006121961A (ja) | 顎骨骨幹異形成症ｇｄｄの原因遺伝子ｇｄｄ１とその用途 | |
| EP1352092B1 (en) | Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis | |
| KR102565803B1 (ko) | 고혈압에 대한 정보 제공 방법 및 이를 이용한 키트 | |
| US20100055709A1 (en) | Tubulin Mutation Diagnostic | |
| CN113234134A (zh) | 一种远端关节挛缩综合症致病基因myh3及其用途 | |
| AU2002224781A1 (en) | Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis | |
| MXPA01012717A (es) | Expresion genica modulada en inflamacion gastrointestinal. | |
| JP2002171990A (ja) | ヒトコレシストキニン遺伝子上流領域の多型、その同定方法及び試薬並びにこれに基づく不安性障害の診断方法 |